Merck Millipore launches Mobius 1000L

Published: 16-Feb-2012
Manufacturing

Single-use mixing and powder delivery system for the preparation of pharmaceutical ingredients

Merck Millipore, the life science division of Merck KGaA, had extended its Mobius mixer series with the addition of the Mobius MIX 1000 and powder delivery system for mixing pharmaceutical ingredients and preparing solutions. It joins a line of mixers that includes 100, 200 and 500 litre sizes.

The Mobius MIX 1000, which uses integrated, single-use powder delivery, mixing, and filtration technology, provides increased operational flexibility and decreases process and validation time and contamination risk, the US-based firm says.

‘We continue to drive innovation in single-use to ensure our customers have the flexibility they need for their manufacturing processes,’ says Paul Chapman, vice president, Biopharm Process Solutions at Merck Millipore.

The new single-use powder delivery container features a butterfly valve for controlled addition of solutes. Its asymmetric design enhances powder delivery by minimising clumping and blockage resulting in optimal powder flow and consistent mixing. The wash down ‘spraybar’ in the powder delivery container ensures that residual powder is effectively removed.

The 1000L uses the same quick-to-start bearingless levitating mixer technology that is the accepted standard within the industry at the 100, 200 and 500L scales. The stainless steel mixer carrier features a double jacket for the sides and the bottom for efficient heat exchange, thermowell for temperature measurement, as well as load cells for weight measurement.

Sampling ports integrated into the Mobius MIX containers provide closed sampling for maintaining product and sample integrity; zero dead-leg to ensure sample collected is representative of the bulk; NovaSeal crimper to easily disconnect the sampling container while maintaining sample and product integrity.

  • Companies:
  • Merck KGAA
See more

You may also like

Manufacturing

Merck Life Science announces closure of Arklow facility

Read more
Merck has said it will close the plant in Co Wicklow, Ireland, by the end of 2028, with the loss of 100 jobs

Trending Articles

  1. Touchlight named most innovative new manufacturing facility at ISPE 2025 Facility of the Year Awards The company’s restored Victorian waterworks site in Hampton, London, has been recognised for transforming DNA manufacturing with its enzymatic, cell-free dbDNA platform
  2. Aseptic spray drying: Transforming biotherapeutics for a new era With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications
  3. ACG to invest $200m in US hard-shell capsule manufacturing ACG will build its first US capsule manufacturing facility in Atlanta, Georgia, with dedicated gelatine and HPMC lines, creating more than 200 jobs and expanding its North American presence ahead of operations starting in early 2027
  4. Roquette opens pharmaceutical innovation centre in Brazil The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
  5. Pharma Partnering US Summit 20225 is all set to commence in Boston on 13–14 November 2025 This high-impact conference brings together top executives from pharma, biotech, investment firms, and advisory groups for two dynamic days of deal-making, networking, and thought leadership

You may also like

Manufacturing

Merck Life Science announces closure of Arklow facility

Merck has said it will close the plant in Co Wicklow, Ireland, by the end of 2028, with the loss of 100 jobs
Manufacturing

Merck opens $1bn US vaccine manufacturing centre in Durham, North Carolina

The extension aligns with Merck's plant to expand its US pharmaceutical manufacturing footprint, with the company planning to invest another $8bn by 2028
Manufacturing

Merck buys WuXi Biologics' Irish vaccine manufacturing facility for $500m

This sale is part of WuXi Biologics' initiative to build business in the face of the BIOSECURE act, as the company places a stronger focus on building its CDMO services in China
Manufacturing

Merck bolsters its ADC CDMO offering with €71m Missouri manufacturing site expansion

The facility's expansion has tripled its ADC manufacturing capacity, bolstering Merck's CDMO offering for current and new clients
Manufacturing

Merck launches single-use reactor designed to accelerate antibody drug conjugate manufacturing

First scalable single-use mixer specifically designed for ADC manufacturing. It increases efficiency by 70% compared to stainless steel or glass manufacturing methods and utilises Ultimus® Film for superior leak resistance
Manufacturing

Merck and Daiichi Sankyo expand antibody drug conjugate commercialisation agreement

The companies will collaborate to commercialise MK-6070, a T-cell engager which has shown promise in treating patients with small cell lung cancer (SCLC)
Manufacturing

Merck expands newest biologics testing centre in Shanghai

New labs complete the second phase of the company’s €29m biologics testing centre, which was opened in 2022
Subscribe now